The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
Abstract
Ovarian cancer (OC) is a lethal gynecological cancer. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in the regulation of cell survival, growth, and proliferation. Irregularities in the major components of the PI3K/AKT/mTOR signaling pathway are common in human cancers. Despite the availability of strong pre-clinical and clinical data of PI3K/AKT/mTOR pathway inhibitors in OC, there is no FDA approved inhibitor available for the treatment of OC. Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Structure and function of matrix metalloproteinases and TIMPs
NAGASE, H., VISSE, R., & MURPHY, G. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.002 · Cited by 3,409
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., & Leal, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293659 · Cited by 887
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Pathology and classification of ovarian tumors
Chen, V. W., Ruiz, B., Killeen, J. L., Cot�, T. R., Wu, X. C., Correa, C. N., & Howe, H. L. (2003) · Cancer · doi:10.1002/cncr.11345 · Cited by 506
Beyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455
Coburn, S. B., Bray, F., Sherman, M. E., & Trabert, B. (2017) · International Journal of Cancer · doi:10.1002/ijc.30676 · Cited by 453
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T., & Noguchi, M. (2000) · PubMed · doi:10.11501/3187985 · Cited by 448
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, S., Kuroda, H., Takahashi, R., & Sasano, T. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.003 · Cited by 413
Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.
Tanner, M., Grénman, S., Koul, A., Johannsson, O. T., Meltzer, P. S., Pejovic, T. B., Borg, Å., & Isola, J. J. (2000) · PubMed · Cited by 317
Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011) · Neoplasia · doi:10.1593/neo.11148 · Cited by 316
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Hu, L., Zaloudek, C. J., Mills, G. B., Gray, J. W., & Jaffe, R. B. (2000) · PubMed · Cited by 301
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.016 · Cited by 295
Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
Gansler, T. S., Hardman, W., Hunt, D. A., Schaffel, S., & Hennigar, R. A. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90177-5 · Cited by 287
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Phospholipase signalling networks in cancer
Park, J. B., Lee, C. S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., & Ryu, S. H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3379 · Cited by 276
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Janku, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 243
Mabuchi, S., Altomare, D. A., Cheung, M., Zhang, L., Poulikakos, P. I., Hensley, H. H., Schilder, R. J., Ozols, R. F., & Testa, J. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2770 · Cited by 234
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
Li, M., Balch, C., Montgomery, J. S., Jeong, M., Chung, J. H., Yan, P., Huang, T. H., Kim, S., & Nephew, K. P. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-34 · Cited by 225
Xiang, Y., Ma, N., Wang, D., Zhang, Y., Zhou, J., Wu, G., Zhao, R., Huang, H., Wang, X., Qiao, Y., et al. (2014) · Oncogene · doi:10.1038/onc.2012.575 · Cited by 225
Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S.-M., Kwiatkowski, D., & Lane, H. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0668 · Cited by 225
Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M., Westin, S. N., Farooq, S., Bell-McGuinn, K. M., Obermayer, E., Whalen, C., Spagnoletti, T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw672 · Cited by 219
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214
Meng, Q., Xia, C., Fang, J., Rojanasakul, Y., & Jiang, B.-H. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.019 · Cited by 214
Behbakht, K., Sill, M. W., Darcy, K. M., Rubin, S. C., Mannel, R. S., Waggoner, S., Schilder, R. J., Cai, K. Q., Godwin, A. K., & Alpaugh, R. K. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.022 · Cited by 211
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Li, H., Zeng, J., & Shen, K. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3377-3 · Cited by 201
Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Dobbin, Z., & Landen, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048213 · Cited by 191
Fu, X., Tian, J., Zhang, L., Chen, Y., & Hao, Q. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.006 · Cited by 187
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Borman, S. M., Christian, P. J., Sipes, I. G., & Hoyer, P. B. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2000.9006 · Cited by 185
Lou (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000530 · Cited by 175
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y., & Zheng, X. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 173
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 163
Crul, M., Rosing, H., de Klerk, G. J., Dubbelman, R., Traiser, M., Reichert, S., Knebel, N. G., Schellens, J. H. M., Beijnen, J. H., & ten Bokkel Huinink, W. W. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00127-2 · Cited by 161
Imam, J. S., Plyler, J. R., Bansal, H., Prajapati, S., Bansal, S., Rebeles, J., Chen, H.-I. H., Chang, Y.-F., Panneerdoss, S., Zoghi, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052397 · Cited by 158
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor
Furuya, F., Hanover, J. A., & Cheng, S.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510849103 · Cited by 147
PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
Gasparri, M. L., Bardhi, E., Ruscito, I., Papadia, A., Farooqı, A. A., Marchetti, C., Bogani, G., Ceccacci, I., Mueller, M. D., & Panici, P. B. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-118907 · Cited by 136
Wang, Y., Guo, R., Guo, R., Wei, S., & Yin, L. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24488 · Cited by 131
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K.-Y. M., Karam, A., Mulholland, D. J., Eng, C., Wu, H., Song, M., & Dorigo, O. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2289 · Cited by 122
Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
Hanrahan, A. J., Schultz, N. D., Westfal, M. L., Sakr, R. A., Giri, D. D., Scarperi, S., Janikariman, M., Olvera, N., Stevens, E. V., She, Q., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0170 · Cited by 118
PIK3CA mutations in advanced ovarian carcinomas
Wang, Y., Helland, Å., Holm, R., Kristensen, G. B., & Børresen‐Dale, A. (2005) · Human Mutation · doi:10.1002/humu.9316 · Cited by 117
Huang, J., Zhang, L., Greshock, J. D., Colligon, T. A., Wang, Y., Ward, R., Katsaros, D., Lassus, H. J., Bützow, R. C., Godwin, A. K., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20883 · Cited by 106
Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Lin, X., Li, T., Roberts, T. M., Zhao, J. J., Cheng, H.-L. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.092 · Cited by 105
Juric, D., Bono, J. S. D., LoRusso, P. M., Nemunaitis, J. J., Heath, E. I., Kwak, E. L., Macarulla, T. M., Geuna, E., Miguel, M. J. D., Patel, C. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2888 · Cited by 103
Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Xu, S., Yang, Z., Jin, P., Yang, X., Li, X., Xiao, W., Wang, Y., Long, S., Zhang, T., Chen, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0927 · Cited by 101
Campone, M., Lévy, V., Bourbouloux, E., Rigaud, D. B., Bootle, D., Dutreix, C., Zoellner, U., Shand, N., Calvo, F. M., & Raymond, É. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604851 · Cited by 97
Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1450 · Cited by 94
A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors
Bessière, L., Todeschini, A., Auguste, A., Sarnacki, S., Flatters, D., Legois, B., Sultan, C., Kalfa, N., Galmiche, L., & Veitia, R. A. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.03.002 · Cited by 93
Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T. M., Zhao, J. J., Liu, P., & Cheng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7549 · Cited by 88
Sheppard, K. E., Cullinane, C. M., Hannan, K. M., Wall, M., Chan, J., Barber, F., Foo, J. H., Cameron, D. P., Neilsen, A., Ng, P. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.007 · Cited by 86
Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer
Kwon, M. J., & Shin, Y. K. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12020983 · Cited by 81
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
Yi, K. H., & Lauring, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6648 · Cited by 77
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
Bailey, H. H., Mahoney, M. R., Ettinger, D. S., Maples, W. J., Fracasso, P. M., Traynor, A. M., Erlichman, C., & Okuno, S. H. (2006) · Cancer · doi:10.1002/cncr.22308 · Cited by 75
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
Schmit, F., Utermark, T., Zhang, S., Wang, Q., Von, T., Roberts, T. M., & Zhao, J. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323004111 · Cited by 75
Emons, G., Kurzeder, C., Schmalfeldt, B., Neuser, P., de Gregorio, N., Pfisterer, J., Park‐Simon, T., Mahner, S., Schroder, W., Lück, H., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.025 · Cited by 75
Genetic deregulation of the PIK3CA oncogene in oral cancer
Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.005 · Cited by 73
Sun, H. Y., Yu, T., & Li, J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.010 · Cited by 71
WU, R. T., Hu, T. C., Rehemtulla, A., Fearon, E. R., & Cho, K. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1388 · Cited by 67
Zervantonakis, I. K., Iavarone, C., Chen, H., Selfors, L. M., Palakurthi, S. S., Liu, J. F., Drapkin, R., Matulonis, U. A., Leverson, J. D., Sampath, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00263-7 · Cited by 67
Pivotal Role of mTORC2 and Involvement of Ribosomal Protein S6 in Cardioprotective Signaling
Yano, T., Ferlito, M., Aponte, A. M., Kuno, A., Miura, T., Murphy, E., & Steenbergen, C. (2014) · Circulation Research · doi:10.1161/circresaha.114.303562 · Cited by 66
Tomek, K., Wagner, R., Varga, F., Singer, C. F., Karlic, H., & Grunt, T. W. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0467 · Cited by 64
Sobinoff, A. P., Nixon, B., Roman, S. D., & McLaughlin, E. A. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs137 · Cited by 62
Bowles, D. W., Ma, W. W., Senzer, N. N., Brahmer, J. R., Adjei, A. A., Davies, M. A., Lazar, A. J., Vo, A. C. H., Peterson, S., Walker, L. N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis
Cai, J., Xu, L., Tang, H., Yang, Q., Yi, X., Fang, Y., Zhu, Y., & Wang, Z. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0333 · Cited by 62
Montero, J. C., Chen, X., Ocaña, A., & Pandiella, A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0723 · Cited by 61
Jebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 61
Type I to Type II Ovarian Carcinoma Progression
WU, R. T., Baker, S. J., Hu, T. C., Norman, K. M., Fearon, E. R., & Cho, K. R. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.031 · Cited by 56
Beltrame, L., Marino, M. D., Fruscio, R., Calura, E., Chapman, B., Clivio, L., Sina, F. P., Mele, C., Iatropoulos, P., Grassi, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv164 · Cited by 54
Pétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 53
Zorea, J., Prasad, M., Cohen, L., Li, N., Schefzik, R., Ghosh, S., Rotblat, B., Brors, B., & Elkabets, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1025-8 · Cited by 52
Lin, Y.-H., Chen, B. Y.-H., Lai, W.-T., Wu, S.-F., Guh, J., Cheng, A., & Hsu, L. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1032-y · Cited by 50
Blagden, S. P., Olmin, A., Josephs, D. H., Stavraka, C., Zivi, A., Pinato, D. J., Anthoney, A., Decordova, S., Swales, K. E., Riisnaes, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1315 · Cited by 46
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
Vlahovic, G., Meadows, K. L., Uronis, H. E., Morse, M. A., Blobe, G. C., Riedel, R. F., Zafar, S. Y., Secord, A. A., Gockerman, J. P., Starodub, A., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1889-8 · Cited by 45
Loganathan, S., Kandala, P. K., Gupta, P., & Srivastava, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043577 · Cited by 45
Kollmannsberger, C., Hirte, H. W., Siu, L. L., Mazurka, J. L., Chi, K. N., Elit, L. M., Walsh, W. R., Sederias, J., Doyle, A., Eisenhauer, E. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr063 · Cited by 42
Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers
Lee, Y., & Park, N.-H. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.031 · Cited by 41
Farley, J. H., Brady, W. E., Fujiwara, K., Nomura, H., Yunokawa, M., Tokunaga, H., Saitou, M., & Gershenson, D. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5531 · Cited by 41
Guo, X., & Ding, X. L. (2018) · Oncology Letters · doi:10.3892/ol.2018.8454 · Cited by 40
Liang, S., Yang, N., Pan, Y., Deng, S., Lin, X., Yang, X., Katsaros, D., Roby, K. F., Hamilton, T. C., Connolly, D. C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004295 · Cited by 37
Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012) · PubMed · Cited by 35
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yu, Y., Hall, T. G., Eathiraj, S., Wick, M. J., Schwartz, B. E., & Abbadessa, G. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000486 · Cited by 28
Inhibiting the RAS–PI3K Pathway in Cancer Therapy
Sheridan, C., & Downward, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00005-6 · Cited by 25
Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
Guo, H., Zhong, Y., Jackson, A. L., Clark, L. H., Kilgore, J., Zhang, L., Han, J., Sheng, X., Gilliam, T. P., Gehrig, P. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7934 · Cited by 18
Iezzi, A., Caiola, E., & Broggini, M. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.011 · Cited by 12
Preclinical study of CC223 as a potential anti-ovarian cancer agent
Jin, Z., Niu, H., Wang, X., Zhang, L., Wang, Q. L., & Yang, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17753 · Cited by 12
Defective DNA repair in hereditary ovarian cancers: Implications for therapy
Burgess, B. T., & Kolesar, J. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180124 · Cited by 9
Cited by
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review
Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Metadata
- Authors
- Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 59
- Pages
- 147-160
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2946007191
- Cited by
- 740
- References
- 129
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.